Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), one of the fastest-growing companies in the global biotechnology industry, has provided a significant boost for the southern region following the announcement last week of further expansion of its Limerick Industrial Operations and Product Supply (IOPS) bioprocessing campus, with an additional 300 jobs and investment of $100 million, bringing the total expected employment at the site to 800 people and total investment to $750 million.
Regeneron’s 400,000 square foot, state-of-the-art production facility in Limerick is the largest scale bulk biologics production facility in Ireland and one of the largest biologic production operations in the world.
The additional $100 million investment will support the construction of a number of manufacturing suites to increase drug substance production capacity and enable the company to meet demand for its life-transforming medicines for patients with serious diseases.
As Regeneron’s Irish expansion continues with employment expected to rise to 800 by the end of 2018, recruitment is ongoing for high-end specialist positions in commercial manufacturing, process sciences, quality assurance/control/validation and various support functions.
Visit www.regeneron.ie to learn more.
The project is supported by the government through IDA Ireland.
